What if you bought Johnson & Johnson in 1990?
US Health · Pharma. The hindsight answer, year by year, against the only benchmark that matters.
Could you have picked it? Play30.0× · S&P 500 same money: $19,429
$1,000 in Johnson & Johnson at the start of 1990 would be worth about $30,000 today — 30.0 times your money, and ahead of the S&P 500 over the same stretch.
The story
Johnson & Johnson is the conglomerate of American medicine cabinets: Band-Aids and Tylenol on one side, prescription drugs and surgical devices on the other. For most of the period it was the definition of a sleepy compounder, with decades of uninterrupted dividend increases and a AAA credit rating that by the 2010s it shared only with Microsoft among US companies.
That does not mean it was scandal-free. Around 2010 a string of quality failures at its McNeil consumer unit led to recalls of children's Tylenol and other products, and later came opioid litigation and tens of thousands of lawsuits alleging its talc baby powder caused cancer, claims the company disputed while repeatedly trying to resolve them through a subsidiary bankruptcy. The stock flatlined for much of the 2000s, then rose as pharmaceutical products like Stelara and Darzalex carried growth. In 2023 the consumer business was spun off as Kenvue, leaving a leaner pharma and medtech company. A buyer in 1990 earned a fine multiple of their money without ever owning the hottest stock in the room.
The lesson: Boring diversified businesses with reliable cash flows rarely top the leaderboard in any single year, yet their steady compounding often beats flashier picks over decades.
$1,000 invested at the start of each year
| Bought in | Price then | Worth today | S&P 500 would be | Multiple |
|---|---|---|---|---|
| 1990 | $6.00 | $30,000 | $19,429 | 30.0× |
| 1995 | $13.00 | $13,846 | $14,783 | 13.8× |
| 2000 | $47.00 | $3,830 | $4,626 | 3.8× |
| 2003 | $54.00 | $3,333 | $7,727 | 3.3× |
| 2005 | $63.00 | $2,857 | $5,763 | 2.9× |
| 2007 | $66.00 | $2,727 | $4,789 | 2.7× |
| 2008 | $67.00 | $2,687 | $4,626 | 2.7× |
| 2010 | $64.00 | $2,812 | $6,071 | 2.8× |
| 2012 | $65.00 | $2,769 | $5,312 | 2.8× |
| 2015 | $104 | $1,731 | $3,301 | 1.7× |
| 2018 | $140 | $1,286 | $2,519 | 1.3× |
| 2020 | $146 | $1,233 | $2,092 | 1.2× |
green = beat the S&P 500 · red = lost money
Best entry point in our set: 1990, turning $1,000 into $30,000. The S&P 500 from that same year: $19,429.
Now try it without hindsight. The wheel decides the year and the asset class, you pick the position, ten seconds a pick, and we simulate to today. Johnson & Johnson is one of 258 positions on the wheel — including the ones that went to zero.
Play Sixty-40More in US Health
- What if you bought Pfizer?
- What if you bought Merck?
- What if you bought Eli Lilly?
- What if you bought Amgen?
- What if you bought Gilead?
- What if you bought Regeneron?